Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
Sijian Wang,M. H. Saboorian,Eugene P. Frenkel,Linda S. Hynan,Sefik T. Gokaslan,Raheela Ashfaq +5 more
Reads0
Chats0
TLDR
This study suggests that the best approach is to combine both IHC and FISH assays; that is, to use the I HC assay as a triage step, followed by the PathVysion FISH assay to analyse the IHC medium and high positive cases.Abstract:
Aim—To evaluate the clinical usefulness of three commercially available assays for Her-2/neu oncogene and protein measurements. The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20–30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin.
Methods—An immunohistochemistry (IHC) assay using the Dako polyclonal antibody A0485, which measures the Her-2/neu protein, was compared with two new Food and Drug Administration (FDA) approved fluorescence in situ hybridisation (FISH) assays—INFORMTM and PathVysionTM, in a cohort of 52 formalin fixed, paraffin wax embedded breast tissues. These tissues were selected randomly from 84 consecutive infiltrating breast cancer specimens, which were first stratified according to the Her-2/neu protein levels as measured by IHC.
Results—The two FISH assays achieved a 98% concordance rate: 14 specimens (27%) showed Her-2/neu gene amplification and 37 specimens (71%) showed no Her-2/neu gene amplification. The PathVysion assay had certain advantages over the INFORM assay. In contrast, the IHC assay detected Her-2/neu overexpression in a high percentage of cases, including 13 high positive specimens (25%) and 13 medium positive specimens (25%). Although 10 of these 13 IHC high positive specimens showed gene amplification by FISH, nine of 13 IHC medium positive specimens showed no gene amplification. Statistical analyses showed that the differences between IHC and FISH assays were primarily in the specimens with medium positive IHC, but negative FISH results.
Conclusions—Because of the increasing importance of the Her-2/neu oncogene and oncoprotein in the clinical management of patients with breast cancer, the accurate and consistent evaluation of Her-2/neu status is crucial. This study suggests that the best approach is to combine both IHC and FISH assays; that is, to use the IHC assay as a triage step, followed by the PathVysion FISH assay to analyse the IHC medium and high positive cases.
Key Words: Her-2/neu • breast cancer • fluorescence in situ hybridisationread more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
BookDOI
European guidelines for quality assurance in breast cancer screening and diagnosis
I Amendoeira,Nicholas Perry,Mireille J. M. Broeders,C de Wolf,Sven Törnberg,Robert Holland,L. von Karsa +6 more
TL;DR: The present supplements to the fourth edition of the European guidelines for quality assurance in breast cancer screening and diagnosis lay a cornerstone for a new, completely revised fifth editions of the guidelines.
Journal ArticleDOI
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross,Elzbieta A. Slodkowska,W. Fraser Symmans,Lajos Pusztai,Peter M. Ravdin,Gabriel N. Hortobagyi +5 more
TL;DR: The review concludes with a consideration of HER-2 status in the prediction of response to non-HER-2 targeted treatments including hormonal therapy, anthracyclines, and taxanes.
Journal Article
European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition - summary document
Nicholas Perry,Mireille J. M. Broeders,Chris de Wolf,Sven Törnberg,Roland Holland,Lawrence von Karsa +5 more
TL;DR: The multidisciplinary editorial board has prepared a summary document to provide an overview of the fundamental points and principles that should support any quality screening or diagnostic service.
References
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Dennis J. Slamon,William Godolphin,Lovell A. Jones,John A. Holt,Steven G. Wong,Duane E. Keith,Wendy J. Levin,Susan G. Stuart,Judy Udove,Axel Ullrich,Michael F. Press +10 more
TL;DR: The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported.
Journal ArticleDOI
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Paul Carter,L. G. Presta,Cornelia M. Gorman,John B. Ridgway,Dennis J. Henner,Wai Lee Wong,A. M. Rowland,Claire Kotts,M. E. Carver,H M Shepard +9 more
TL;DR: The murine monoclonal antibody mumAb4D5, directed against human epidermal growth factor receptor 2 (p 185HER2), specifically inhibits proliferation of human tumor cells overexpressing p185HER2, but the efficacy of mumAb 4D5 in human cancer therapy is likely to be limited by a human anti-mouse antibody response and lack of effector functions.
Journal Article
Prognostic and predictive factors in breast cancer by immunohistochemical analysis
TL;DR: Although available studies suggest that estrogen and progesterone receptors might indeed be helpful in making treatment decisions, their clinical usefulness is still controversial, and there are important unresolved technical issues, such as how to prepare the tissue, which reagents to use and, most importantly, how to interpret the results.
Journal Article
Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts
TL;DR: The combination of pac litaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhu MAb Her2 alone.